



# Pharmaceuticals Pipeline Overview<sup>1</sup>

(as of July 21, 2026)

Oncology

Cardiovascular & Renal

Neurology & Rare Diseases

Immunology

Others

## Phase I

|                                                                                  |                                                                                         |
|----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
| <b>VVD KEAP1 Activator</b> (VVD-130037 aka <i>NRF2 Inh</i> , BAY 3605349)        |  NME   |
| <b>Actinium (225Ac) Felivotide Mopaxetan</b> (BAY 3563254)                       |  NME   |
| <b>SOS1 Inhibitor</b> (BAY 3498264)                                              |  NME   |
| <b>PRMT5 Inhibitor</b> (BAY 3713372)                                             |  NME   |
| <b>VVD RAS-PI3K Inhibitor</b> (VVD-159642, BAY 3674171)                          |  NME   |
| <b>225Ac-GPC3</b> (BAY 3547926)                                                  |  NME   |
| <b>VVD WRN Inhibitor</b> (VVD-133214, BAY 3772392)                               |  NME   |
| <b>KRAS G12D Inhibitor</b> (BAY 3771249)                                         |  NME   |
| <b>Dual FIIa/Xa Inhibitor</b> (BAY 3389934)                                      |  NME   |
| <b>GIRK4 Inhibitor</b> (BAY 3670549)                                             | NME                                                                                     |
| <b>BAY 3620122</b>                                                               |  NME   |
| <b>Ametefgene Parvec</b> (AAV Gene Therapy) (AB-1005)<br>Multiple System Atrophy |  NME   |
| <b>Pompe Disease AAV Gene Therapy</b> (AB-1009 aka <i>PROGRESS-GT LOPD</i> )     |  NME |
| <b>LGMD2I/R9 AAV Gene Therapy</b> (AB-1003 aka <i>LION-101</i> )                 |  NME |
| <b>Primary Photoreceptor Diseases Cell Therapy</b> (BRT-OpCT-001)                |  NME |
| <b>AT-05 SPECT Tracer</b>                                                        |  NME |

## Phase II

|                                                                                                                                                 |                                                                                         |
|-------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
| <b>Sevabertinib</b> (HER2/mEGFR Inhibitor) (BAY 2927088)<br>// Metastatic or Unresectable Solid Tumors With HER2-activating Mutations (panSOHO) |  IE  |
| <b>Umiposgene Parvec</b> (AAV Gene Therapy) (AB-1002)<br>// Congestive Heart Failure (GenePHIT)                                                 |  NME |
| <b>Inclocibart</b> (anti-a2AP) (BAY 3018250)<br>// Acute Ischemic Stroke; Pulmonary Embolism (SIRIUS)                                           |  NME |
| <b>Nurandociguat</b> (sGC Activator Oral) (BAY 3283142)<br>// Chronic Kidney Disease (ALPINE-1)                                                 |  NME |
| <b>SEMA 3a Inhibitor</b> (BAY 3401016)<br>// Alport Syndrome (ASSESS)                                                                           |  NME |
| <b>Ametefgene Parvec</b> (AAV Gene Therapy) (AB-1005)<br>// Parkinson's Disease (REGENERATE-PD)                                                 |  NME |
| <b>Edonentan</b> (ER Antagonist) (PER-001, BAY 3826827)<br>// Non-proliferative Diabetic Retinopathy<br>// Glaucoma                             |  NME |

## Phase III

|                                                                                                                                                                        |                                                                                         |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
| <b>Darolutamide</b> (AR Inhibitor)<br>// Adjuvant Prostate Cancer (DASL-HiCaP)<br>// Prostate Cancer with Biochemical Recurrence after Curative Radiotherapy (ARASTEP) |  IE  |
| <b>Finerenone</b> (MR Antagonist)<br>// Non-diabetic Chronic Kidney Disease (FIND-CKD)                                                                                 |  IE  |
| <b>Bemdaneprocel</b> (Cell Therapy)<br>// Parkinson's Disease (exPDite-2)                                                                                              |  NME |
| <b>124I-Evuzamitide</b> (PET Tracer)<br>// Diagnosis of Cardiac Amyloidosis (REVEAL)                                                                                   |  NME |

## Submissions

|                                                                                                        |                                                                                                                                                                                   |
|--------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Sevabertinib</b> (HER2/mEGFR Inhibitor)<br>// CN, US: Advanced NSCLC 1L<br>// JP: HER2-mut NSCLC 2L |  IE<br> NME |
| <b>Finerenone</b> (MR Antagonist)<br>// US: Chronic Kidney Disease in Type 1 Diabetes                  |  IE                                                                                          |
| <b>Asundexian</b> (FXIa Inhibitor)<br>// CN, EU, JP, US: 2° Stroke Prevention                          |  NME                                                                                         |
| <b>Aflibercept 8mg</b> (VEGF-Inhibitor)<br>// CN: Retinal Vein Occlusion                               |  IE                                                                                          |
| <b>Gadoquatrane</b> (High Relaxivity Contrast Agent)<br>// EU, CN: Magnetic Resonance Imaging          |  NME                                                                                         |

 Small Molecule    Radionuclide Therapy    Genetic Therapy    Cell Therapy    Imaging Agent    Protein Therapy

NME New Molecular Entity   IE Indication Expansion

<sup>1</sup> Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit